RK Pharma said the acquisition will give the company an exciting product portfolio, meaningful partnerships and a proven team with an impressive track record.
The plan highlights the most critical challenges preventing patient access to biosimilar medicines, as well as actionable steps to accelerate adoption by overcoming those challenges.
The injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to specific factors.
